THE RESULTS OF TREATMENT OF STAGE II-III DISTAL GASTRIC ADENOCARCINOMA UNDERWENT SURGERY AND POSTOPERATIVE CHEMORADIATION THERAPY

Abstract

Objectives: To evaluate the survival outcome, patterns of failure, and complications in patients treated with postoperative chemoradiation therapy in stages II-III of distal gastric cancer. Materials & methods: Prospective study on 58 patients with stages II-III gastric adenocarcinoma, underwent distal gastrectomy and D1 or D2 dissection, completed post operative chemoradiation therapy with capecitabine and 4-6 cycles with EOX regimen at Oncology center of Hue central hospital from 01/2013 to 12/2015. Results: Mean age was 55.16 ± 9.1, male/female ratio: 3/1, recurrence was common in the first year after treatment (62.5%), the average time of recurrence and metastasis were 13.50 ± 7.29 months and 18.75 ± 8.97 months, respectively. The mean overall survival was 41.21 ± 21.06 months. The mean disease free survival was 36.22 ± 22.64 months. The mean overall survival: stage II was 41.88 ± 20.78 months; stage III was 39.59 ± 22.27. The mean overall survival for extention of primary tumors: T3 was 40.79 ± 19.61 months; T4 was 41.33 ± 24.80 months. The mean overall survival for extensive of lymph nodes: N (-) was 41.16 ± 20.51 months, N (+) was 41.26 ± 22.06 months. Toxicity levels recorded as follow: leukopenia was mainly on grade 1 and 2 (33.6%), neutropenia was mostly on grade 1 and 2 (26.8%), as well as thrombocytopenia (8.6%); hemoglobin decrease was on grade 1 and 2 in most cases (41.4%); toxicity symptoms on digestive system like nausea-vomitting, diarrhea was mainly on grade 1 and 2. Conclusion: Postoperative chemoradiation therapy helps to improve local and regional recurrence in locally advanced gastric cancer with acceptable toxicities. Key words: Distal gastric adenocarcinoma, postoperative chemoradiation therapy